



**ENDOTHELIAL DAMAGE  
FROM COVID IN VENOUS  
DISEASE AND POTS**



Jordan Vaughn, M.D.

**Dr. Jordan Vaughn**  
IMA Senior Fellow, Microvascular Disease



# Endothelial Damage from COVID in Venous Disease and POTS

*With*

**Dr. Jordan F Vaughn**

- May-Thurner (Pelvic Venous Disease) Plus MCAS and OI (Orthostatic Intolerance) or POTS following Endothelial Injury (Spike Protein)


- **Common in:**

- Hypermobile: EDS or EDS Like
- Runners/Cyclist/Pelvic Trauma/Horseback Riders?
- Multiparous Women/Pelvic Inflammation History (Endometriosis et al)
- Men with Scrotal Fullness/Testicle History/NewED? including Varicocele, Torsion, Pudendal Nerve Pain

- **Often Results in Lower Extremity Symptoms Initially.**

- Most Remember a TIME and DATE when things in their body were DIFFERENT
- Many had Mild issues prior including Leg going to sleep when sitting for long times mild Orthostatic Intolerance

- Often but not Always: Symptoms Initially Lower Ext/Muscles Heavy, Fail to Recover with Exercise
- POTS/OI and MCAS symptoms increased.
- Triple Therapy (Antiplatelet and AntiCoags) Help but not Curative



Spencer E, Elhage Hassan M, Saikia J et al. **Association and post-iliac vein stenting symptom improvement of postural orthostatic tachycardia syndrome and orthostatic intolerance with pelvic venous disorders: two retrospective studies.** eClinicalMedicine, 2026; 92

- Additional Issues:
  - Urinary Urgency or 'Frequent Urinary Tract Infections' or Interstitial Cystitis
  - Heavy Menstrual Cycles, Pelvic Pain, all Issues are worse before and during cycle
  - Hemorrhoids and Irritable Bowel Symptoms (Absorption and Transit Issues)
  - Lower Sacral Back Pain and Sacral Ileitis Symptoms
  - Hip Pain or Non healing Lower Extremity Injury or Procedure
    - (ex. Labral Tear of L Hip or Stress Fracture in Athlete)
  - Men: Boggy Prostate and Nocturia in Younger Men.

Spencer E, Elhage Hassan M, Saikia J et al. **Association and post-iliac vein stenting symptom improvement of postural orthostatic tachycardia syndrome and orthostatic intolerance with pelvic venous disorders: two retrospective studies.** eClinicalMedicine, 2026; 92



Flank pain, hematuria, proteinuria

- Systemic symptoms**
- Cardiovenous syndrome—exertional dyspnea, heart failure
  - Post-thrombotic syndrome
  - Unexplained pulmonary emboli




- Pelvic symptoms**
- Chronic pelvic pain (CPP)
  - Perineal varicosities

- Renal symptoms**
- Flank pain
  - Hematuria
  - Proteinuria


- Extra pelvic symptoms**
- Lower limb, vulvar varicosities
  - Lower limb swelling
  - Venous claudication



Sheikh AB, Fudim M, Garg I, Minhas AMK, Sobotka AA, Patel MR, Eng MH, Sobotka PA. The Clinical Problem of Pelvic Venous Disorders. Interv Cardiol Clin. 2022 Jul;11(3):307-324. doi: 10.1016/j.iccl.2022.03.003. PMID: 35710285.



Sheikh AB, Fudim M, Garg I, Minhas AMK, Sobotka AA, Patel MR, Eng MH, Sobotka PA. The Clinical Problem of Pelvic Venous Disorders. *Interv Cardiol Clin*. 2022 Jul;11(3):307-324. doi: 10.1016/j.iccl.2022.03.003. PMID: 35710285.



Sheikh AB, Fudim M, Garg I, Minhas AMK, Sobotka AA, Patel MR, Eng MH, Sobotka PA. The Clinical Problem of Pelvic Venous Disorders. *Interv Cardiol Clin.* 2022 Jul;11(3):307-324. doi: 10.1016/j.iccl.2022.03.003. PMID: 35710285.

# Spike Protein or Immune response to viral infection or vaccination Mediated Injury to Vasa Vasorum and Vein Wall Muscle

## 1. Bind ACE2 Receptors

- ACE2 is expressed on **endothelial cells**, including those of the **vasa vasorum**.
- Binding disrupts **ACE2 signaling**, leading to:
  - **Endothelial dysfunction**
  - **Oxidative stress**
  - **Pro-thrombotic and pro-inflammatory states**

## 2. Trigger Endotheliitis

- COVID Virus Antigen can directly activate **inflammatory pathways** (e.g., **NF-κB**, **TLR4**) in endothelial cells.
- This leads to **immune cell infiltration**, **microthrombosis**, and **capillary leak**—
- **particularly damaging to the fragile vasa vasorum**.

## 3. Promote Microclot Formation

- Spike protein interacts with **fibrinogen**, altering clot architecture.
- Resulting **fibrin-rich microclots** are resistant to breakdown and may **occlude vasa vasorum**.

## 4. Induce Autoimmunity


- Molecular mimicry or immune priming can lead to **autoantibodies targeting endothelial cells**, platelets, or coagulation factors.
- This immune response may persist and cause **ongoing vascular injury**, especially in predisposed individuals (e.g., those with **MCAS, POTS, or connective tissue disease**).

1. Robles JP, Zamora M, Adan-Castro E, et al. The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin  $\alpha 5\beta 1$  and NF- $\kappa$ B signaling. *J Biol Chem*. 2022;298(3):101695.
2. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2. *Circ Res*. 2021;128(9):1323–1326.
3. Raghavan S, Kenchappa DB, Leo MD, et al. SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication. *Sci Rep*. 2023;13:41115.
4. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? *Cardiovasc Res*. 2020;116(10):e163–e165.
5. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J*. 2020;41(32):3038–3044.
6. Zhang J, Tecson KM, McCullough PA. Endothelial dysfunction contributes to COVID-19-associated vascular inflammation and coagulopathy. *Rev Cardiovasc Med*. 2020;21(3):315–319.
7. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID. *Cardiovasc Diabetol*. 2021;20:172.
8. Grobbelaar LM, Venter C, Vlok M, et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis. *Biochem J*. 2021;478(3):537–550.
9. Kell DB, Pretorius E. Persistent clotting abnormalities in long COVID. *J Thromb Haemost*. 2022;20(4):1–13.
10. Nyberg EM, et al. SARS-CoV-2 spike protein drives fibrin-mediated inflammation. *Blood Advances*. 2022;6(7):2286–2299.
11. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. *Nat Rev Immunol*. 2020;20:389–391.
12. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*. 2020;395(10234):1417–1418.
13. Chioh FW, Fong SW, Young BE, et al. Convalescent COVID-19 patients exhibit persistent endothelial dysfunction. *Circulation*. 2021;143(15):1474–1476.
14. Evans PC, Rainger GE, Mason JC, et al. Endothelial dysfunction in COVID-19: mechanisms and implications. *Nat Rev Immunol*. 2020;20:389–391.
15. Bernard I, Limonta D, Mahal LK, Hobman TC. Endothelium infection and dysregulation by SARS-CoV-2. *Trends Microbiol*. 2021;29(7):596–598.
16. Siddiqi HK, Libby P, Ridker PM. COVID-19 – a vascular disease. *Trends Cardiovasc Med*. 2021;31(1):1–5.
17. Bermejo-Martin JF, Almansa R, Menéndez R, et al. Lymphopenic community acquired pneumonia is associated with an impaired adaptive immune response. (Supports immune dysregulation / autoimmunity context)
18. Wenzel P, Kopp S, Göbel S, et al. Evidence of systemic endothelial dysfunction in COVID-19. *Eur Heart J*. 2020.
19. Vargas-Alarcón G, Posadas-Sánchez R, Ramírez-Bello J, et al. Autoimmunity and COVID-19: molecular mimicry mechanisms. *Autoimmun Rev*. 2021;20(3):102679.
20. Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection. *Eur Respir J*. 2020;56(1):2001634.

## Impact on the Muscular Layer of Large Veins

When the **vasa vasorum** are damaged, the result is **ischemic injury to the tunica media**, including:

- **Smooth Muscle Cell Apoptosis**
  - From hypoxia or direct inflammatory signaling
- **Wall Weakening and Fibrosis**
  - Reduced contractility, increased stiffness
- **Vein Dilation and Valvular Dysfunction**
  - Contributing to **chronic venous insufficiency**
- **Loss of Vessel Tone**
  - Especially relevant in dysautonomia and orthostatic intolerance seen post-vaccine or post-infection



Herrmann J, et al. Am J Pathol. — Vasa vasorum supply the adventitia and outer media  
 Osada H, Minatoya K. Surg Today. 2022 — Vasa vasorum dysfunction leads to medial hypoxia and degeneration  
 Tanaka H, et al. Front Cardiovasc Med. 2018 — Medial hypoxia associated with vasa vasorum remodeling  
 Kwon HM, et al. Eur J Cardiothorac Surg. — Vasa vasorum occlusion causes medial necrosis  
 Maiellaro K, Taylor WR. Circulation. 2007 — Role of adventitia and vasa vasorum in vascular inflammation  
 Moulton KS, et al. — Vasa vasorum facilitate inflammatory cell infiltration into vessel wall  
 Hu J, et al. Nat Rev Cardiol. 2024 — Smooth muscle dysfunction and fibrosis drive vascular stiffness  
 Shimizu K, et al. — Vasa vasorum ischemia contributes to plaque instability and wall injury

## Step 1: Venous Wall Damage

- **Hypoxia of tunica media** from vasa vasorum occlusion →
  - ▼ Smooth muscle apoptosis
  - ▼ Fibrosis
  - ▼ Loss of compliance
  - ▼ Venous dilation or collapse


## Step 2: Venous Compression Syndromes

- Injured or fibrosed veins are prone to **mechanical compression** at known anatomical choke points:
  - **Left common iliac vein** (May-Thurner syndrome)
  - **Jugular or brachiocephalic vein** (thoracic outlet compression)
  - **Left renal vein** (Nutcracker syndrome)
- Can lead to:
  - **Collateral vein formation**
  - **Stagnant flow**
  - **Further clotting or inflammation**

Davis, B.M.; Rantanen, P.; Seo, G.; Thadani, S.; Spencer, E.B.; Hepworth, E.; Cutchins, A. An Overview of Vascular Compression Syndromes and Associations with Autonomic Dysfunction: A Review. *Biomedicines* 2026, 14, 689. <https://doi.org/10.3390/biomedicines14030689>

### Step 3: Right Heart Preload Failure

- Impaired **venous return** reduces **right ventricular preload**.
- Consequences:
  - **Low cardiac output**
  - **Reduced pulmonary perfusion**
  - **Exertional fatigue**
  - **Orthostatic intolerance**




Sheikh AB, Fudim M, Garg I, Minhas AMK, Sobotka AA, Patel MR, Eng MH, Sobotka PA. The Clinical Problem of Pelvic Venous Disorders. *Interv Cardiol Clin*. 2022 Jul;11(3):307-324. doi: 10.1016/j.iccl.2022.03.003. PMID: 35710285.

## Step 4: Hypocapnic Cerebral Hypoperfusion

- **Low preload + low CO<sub>2</sub>** leads to:
  - **Cerebral hypoperfusion**—exacerbated by hyperventilation and **hypocapnia** (low CO<sub>2</sub>)
- **Pathophysiology:**
  - **Hypocapnia** (low arterial CO<sub>2</sub>) results from hyperventilation or abnormal respiratory patterns.
  - Decreased CO<sub>2</sub> (a powerful cerebral vasodilator) leads to **cerebral vasoconstriction**.
  - Vasoconstriction reduces cerebral blood flow (CBF), causing **cerebral hypoperfusion**.
- Symptoms:
  - **Brain fog**
  - **Lightheadedness**
  - **POTS-like features**
  - **Visual and cognitive disturbances**

Davis, B.M.; Rantanen, P.; Seo, G.; Thadani, S.; Spencer, E.B.; Hepworth, E.; Cutchins, A. An Overview of Vascular Compression Syndromes and Associations with Autonomic Dysfunction: A Review. *Biomedicines* 2026, 14, 689. <https://doi.org/10.3390/biomedicines14030689>



Davis, B.M.; Rantanen, P.; Seo, G.; Thadani, S.; Spencer, E.B.; Hepworth, E.; Cutchins, A. An Overview of Vascular Compression Syndromes and Associations with Autonomic Dysfunction: A Review. *Biomedicines* 2026, 14, 689. <https://doi.org/10.3390/biomedicines14030689>

## Cerebral Blood Flow is Closely Tied to EtCO<sub>2</sub>:

- Every **1 mmHg drop** in EtCO<sub>2</sub> is associated with **~3% cerebral blood flow reduction**
- Novak's HYCH and POTS cohorts had **EtCO<sub>2</sub> drops >12 mmHg**, predicting **~36% cerebral perfusion loss**
- This degree of **hypocapnic vasoconstriction** explains the:
  - Orthostatic **brain fog, dizziness, lightheadedness**
  - **Cognitive decline** in chronic cases
  - Enhanced **central sensitization**

Novak P, et al. "Orthostatic intolerance with tachycardia and without represent a spectrum of the same disorder." *Frontiers in Neurology*. 2024.

## A Clinical Way to Assess this with Orthostatic End Tidal CO<sub>2</sub> Measurements

Variable	Controls	HYCH	POTS	p-value
Supine EtCO <sub>2</sub> (mmHg)	38.43 ± 1.74	36.18 ± 3.47	34.88 ± 3.92	<0.001
Orthostatic EtCO <sub>2</sub> (mmHg)	35.21 ± 1.60	28.60 ± 5.32	25.22 ± 5.28	<0.001
Max Δ EtCO <sub>2</sub> (orthostatic)	-3.98 ± 0.90	-11.98 ± 3.86	-12.95 ± 4.35	<0.001
Max % drop in EtCO <sub>2</sub>	-10.33%	-33.25%	-37.31%	<0.001
Mean CBFv drop (orthostatic)	-8.57%	-29.21%	-31.53%	<0.001
Preload failure (from iCPET)	0%	100%	100%	—

### Clinical Application:

#### Protocol:

1. Measure baseline EtCO<sub>2</sub> **supine after 5 min rest**
2. Measure EtCO<sub>2</sub> **after 5–10 min standing or tilt**
3. Monitor for:

- **ΔEtCO<sub>2</sub> ≥10 mmHg**
- Absolute EtCO<sub>2</sub> **<30 mmHg**
- Symptoms of **lightheadedness, dizziness, visual fog**

**Significant drop in EtCO<sub>2</sub> during standing is a marker of preload failure and cerebral vasoconstriction, even in the absence of tachycardia**

Source: Novak P, et al. "Orthostatic intolerance with tachycardia and without represent a spectrum of the same disorder." *Frontiers in Neurology*. 2024.

## Journal Pre-proof

Concentration of Inflammatory Markers in Plasma of Varicose Ovarian Veins in Women With Pelvic Venous Disorders: A Pilot Study

Marcin Czezelewski, Eryk Mikos, Sara Moqbil, Maciej Szmygin, Hanna Szmygin, Krzysztof Pyra



PII: S1078-5884(23)00456-2

DOI: <https://doi.org/10.1016/j.ejvs>

Reference: YEJVS 8824

To appear in: *European Journal of Vascular & Endovascular Surgery*

Received Date: 29 December 2022

Revised Date: 16 May 2023


Accepted Date: 14 June 2023

**Table 1. Comparison of blood counts and levels of inflammatory markers in samples from the antecubital vein and pelvic varicose vein of 25 patients of reproductive age referred for endovascular treatment of pelvic venous disorder.**

Variable	Antecubital vein <i>n</i> = 25	Pelvic varicose vein <i>n</i> = 25	<i>p</i>
Erythrocytes – 10 <sup>12</sup> /L	4.02 (3.17 – 4.91)	4.23 (3.30 – 4.86)	.002
Leukocytes – 10 <sup>9</sup> /L	4.62 (2.98 – 6.52)	5.21 (3.30 – 8.34)	.001
Platelets – 10 <sup>9</sup> /L	220.5 (163 – 279)	237 (196 – 302)	.005
Haemoglobin – g/dL	12.00 (9.70 – 15.20)	12.95 (10.80 – 15.40)	.001
D-dimer – pg/mL	9 884 (2 259 – 16 910)	13 330 (3 099 – 114 110)	.081
C-reactive protein – mg/L	0.15 (0.12 – 2.93)	0.24 (0.10 – 3.04)	.038
Fibrinogen – g/L	2.25 (1.7 – 4.50)	2.25 (1.60 – 3.60)	.410
Interleukin-6 – pg/mL	50.88 (36.58 – 87.16)	57.14 (40.03 – 79.38)	.038
von Willebrand – ng/mL	36.28 (21.15 – 168.6)	45.43 (20.68 – 89.00)	.442

Data are presented as median (range).

# Mast Cell Activation Syndrome



**Figure 1.** The most common presenting symptoms and potential triggers of mast cell activation.<sup>1,2,4</sup> Symptoms and triggers are unique to the individual. Specific criteria, as noted in the article text, must be met to fulfill a diagnosis of MCAS. Not all patients react to each of the listed triggers or experience each of the listed symptoms. Mast Cell Activation Symptoms and Triggers Infographic 2021 printed with permission from The Mast Cell Disease Society, Inc (DBA The Mastocytosis Society, Inc). The superscript letter "a" indicates symptoms reported by more than 45% of TMS MCAS survey respondents as affecting them either moderately or severely in the course of their illness with MCAS.<sup>3</sup> The superscript letter "b" indicates symptoms not queried in the TMS MCAS survey. DBA, doing business as; MCAS, mast cell activation syndrome; TMS, The Mast Cell Disease Society, Inc.

# Mast Cells in the Tunica Externa of the Large Vein Walls









Figure 1. Localization and distribution of mast cells (MCs) in vein. (A,B): Illustration of MC localization in human saphenous vein: several 4 μm sections of healthy saphenous vein (hSV, (A)) or varicose saphenous vein (vSV, (B)) were stained with double horseradish peroxidase staining. Red staining: MCT. Brown staining: MCTC. Black bar: 100 μm, white bar: 10 μm. (C): Distribution of MCT and MCTC in both hSV (n = 3) and vSV (n = 5). (D): Overview of total MC counted per mm<sup>2</sup> in hSV (n = 3) and vSV (n = 5). \* p < 0.05, n.s.: non-significant p-value.

Callesen, K.T.; Mogren, S.; Berlin, F.; Andersson, C.; Schmidt, S.; Klitfod, L.; Esteban, V.; Poulsen, L.K.; Jensen, B.M. Characterization of Mast Cells from Healthy and Varicose Human Saphenous Vein. *Biomedicines* **2022**, *10*, 1062. <https://doi.org/10.3390/biomedicines10051062>


# Venography of Iliac Vein and Intervention



# OVERVIEW

30% of blood volume is in the thorax while supine


300-800ml of blood gravitates to the abdomen and lower extremities with standing (10-25% of plasma volume shifts into the interstitial tissues)



In normal patients this results in 10-15 bpm increase in HR and increase in diastolic BP of 5-10mmHg

W Weiling MD et al. Diagnosis and treatment of orthostatic hypotension. The Lancet Neurology. Volume 21, Issue 8, August 2022, Pages 735-746

# OVERVIEW



Adapted from: W Weiling MD et al. Diagnosis and treatment of orthostatic hypotension. The Lancet Neurology. Volume 21, Issue 8, August 2022, Pages 735-746

# Another Phenotype: ILIAC VEIN COMPRESSION

## Non-Invasive Interventions to help

### Medications:

- Anticoagulation/Antiplatelet
  - Low Dose Aspirin and DOAC (Eliquis)
  - Pentoxifylline (Increases Oxygen Delivery/Antithrombotic/Antiplatelet)
- Mast Cell Stabilization:
  - H1 and H2 Blockade (Xyzal/Allegra plus Famotidine)
  - Mast Cell Stabilizers
    - Compounded Oral Ketotifen 1mg Twice a day
    - Cromolyn Sodium (Best for MCAS with GI issues)
    - Quercetin (High Dose 1gram to 2 Grams/Turmeric/Curcumin/Black Pepper)
- Endothelial Repair:
  - Diosmin 500mg-750mg Daily; Pycnogenol 50mg Twice a day
  - SGLT-2i (Jardiance etc)
- Increase Intravascular Volume:
  - Salt/Hydration
  - Fludrocortisone

# Another Phenotype: ILIAC VEIN COMPRESSION

## Non-Invasive Interventions to help

Physical Interventions: **Venous System is LOW Pressure and w/o a PUMP**

◦ Increase Venous Return:

■ Low Extremity Movement = Venous Pumping

• Walking

• Recumbent Biking or Rowing: (Horizontal Means Lower Pressures to Work Against)

◦ IVC Pressure Lying Down: **8-10mmhg** versus Standing Up: **20-22mmhg**

• Typically Feel almost Normal in Water (Bath, Pool, Ocean)

◦ Buoyance of Water Decrease Gravitational Gradient

◦ Weight of Water Acts Like Whole Body Venous Compression Device as Weight of Water

Augments Venous Return.

■ Compression Stockings: ( Ok but Not Dynamic: Veins Muscle work in concert with Muscle Pumping )

# Non-Invasive Interventions to help

Physical Interventions: **Venous System is LOW Pressure and w/o a PUMP**

## ◦ Intermittent Compression Devices:

- For 20-30 Minutes Prior to Bedtime and 20-30 Min upon Waking or for Recovery
- Remember legs (aka venous Pump) moves Minimally During (Normal) Sleep
- We Sleep Horizontal because of the Venous System not the Arterial System



## ◦ Dynamic Muscle Stimulation Devices:

- For use when sitting for Long Periods, Travel, or Recovery from Exertion/Exercise
- Firefly Muscle Recovery



# Another Phenotype: ILIAC VEIN COMPRESSION

## Non-Invasive Interventions to help

Physical Interventions: **Venous System is LOW Pressure and w/o a PUMP**

- Current Trial Using High Frequency Ultrasound Technology Directly on Iliac Vein
  - Weekly to Biweekly Treatments in those with Mild to Moderate Compression
  - So Far Outcomes have been Promising.



ARTICLES · Volume 92, 103772, February 2026 · Open Access

Download Full Issue


# Association and post-iliac vein stenting symptom improvement of postural orthostatic tachycardia syndrome and orthostatic intolerance with pelvic venous disorders: two retrospective studies

Elizabeth Brooke Spencer <sup>a</sup> · Malika Elhage Hassan <sup>b</sup> · Junmi Saikia <sup>c</sup> · Deeksha Ajeya <sup>d</sup> · Raquel Phillips <sup>a</sup> · Rebecca S. Steinberg <sup>e</sup> · et al. [Show more](#)

[Affiliations & Notes](#) [Article Info](#)

[Download PDF](#) [Cite](#) [Share](#) [Set Alert](#) [Get Rights](#) [Reprints](#)

[Previous article](#) [Next article](#)



## Summary

Show Outline

### Background

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and Orthostatic Intolerance (OI) commonly present with symptoms suggestive of Pelvic Venous Disorders (PeVD). The presence of PeVD may contribute to orthostatic symptoms in these patients due to venous obstruction with stasis and pooling. Iliac vein compression, a PeVD, has historically been treated with iliac venous stenting. The authors hypothesize that patients with POTS frequently have findings of PeVD, that venous outflow obstruction from iliac vein compression exacerbates POTS/OI symptomatology, and that treating PeVD improves POTS/OI symptoms.

## Figures (7)

Figure Viewer





# Pelvic Venous Compression in Patients with Postural Orthostatic Tachycardia Syndrome

Malika Elhage Hassan, Siya Thadani, Catherine McGeoch, Rebecca Steinberg, Mariana Garcia, Zakaria Almuwaqqat, Kristina Bortfeld, Alexis Cutchins  
Emory University School of Medicine, Atlanta, GA

Department of Medicine

## Introduction

Patients with Postural Orthostatic Tachycardia Syndrome (POTS) commonly present with orthostatic intolerance along with pelvic pain, lower back pain, leg pain/edema, urinary symptoms, dysmenorrhea/menorrhagia, and gastrointestinal symptoms. This constellation of symptoms suggests evidence of pelvic venous disease that may contribute to orthostatic symptoms in these patients, due to venous obstruction with stasis and pooling. We hypothesized that patients with POTS frequently had findings of pelvic venous disease.

## Methods

Patients formally diagnosed with POTS were assessed for pelvic venous compression via pelvic venous ultrasound, MR angiography or venography, CT angiography or venography, and/or venogram with intravascular ultrasound.

## Results

94 patients with a diagnosis of POTS presenting to a single healthcare center were screened. 21 patients were excluded from analysis due to incomplete work up with pending imaging results. The remaining 73 patients (93% female) were assessed for pelvic venous disease. Symptoms of pelvic venous disease, documented in the patient's chart, were common in this population (Table). 56 patients had confirmed pelvic venous compression (iliac vein, renal vein or both) on imaging with at least one modality.

## Summary and Conclusions

77% of our POTS patients were diagnosed with pelvic venous compression, suggesting an association between the two diagnoses. Future studies should investigate the progression of POTS outcomes and pelvic imaging findings after intervention, such as stenting, to alleviate the pelvic venous compression.


## Results

Table: Frequency of Symptoms and Diagnosis of Pelvic Venous Compression in Patients with Postural Orthostatic Tachycardia Syndrome

	Number of patients (N=73)
Pelvic pain or heaviness	45 (62%)
Lower back pain	21 (29%)
Lower extremity pain	36 (49%)
Lower extremity edema	43 (59%)
Lower extremity discoloration	14 (19%)
Varicose veins	19 (26%)
Urinary symptoms (frequency/urgency/dysuria)	42 (58%)
Dysmenorrhea/menorrhagia (N=68)	35 (51%)
Upper gastrointestinal symptoms (heartburn/nausea)	49 (67%)
Lower gastrointestinal symptoms (constipation/diarrhea)	44 (60%)
Pelvic venous compression confirmed on imaging	56 (77%)

## Discussion

Figure: Proposed relationship between Pelvic Venous Disease and Postural Orthostatic Tachycardia Syndrome



## Preprints with THE LANCET

Preprints with *The Lancet* is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not *Lancet* publications or necessarily under review with a *Lancet* journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the [FAQs](#).

# Symptomatic Improvement in Orthostatic Intolerance and Postural Orthostatic Tachycardia Syndrome and Pelvic Pain after Iliac Vein Stenting

17 Pages • Posted: 15 May 2025

[Elizabeth Brooke Spencer](#)

Minimally Invasive Procedure Specialists LLC

[Junmi Saikia](#)

UHS Southern California Medical Education Consortium

[More...](#)

[Click here to go to TheLancet.com](#)

[Go to TheLancet.com](#)

### Paper statistics

DOWNLOADS	ABSTRACT VIEWS
300	1,647

30 [References](#)

PlumX Metrics



### Preprints with The Lancet Specialties

[All Journals \(20979\)](#)

[Allergy & Immunology \(1105\)](#)

[Anaesthesia & Analgesia \(55\)](#)

# Thank you

For more medical education visit  
[www.IMAhealth.org](http://www.IMAhealth.org)

